Tag: Incyte

Latest News

FDA erteilt Zulassung für Pemazyre™ (Pemigatinib) von Incyte als erste gezielte Therapie für Erwachsene mit vorbehandeltem, inoperablem, lokal fortgeschrittenem oder metastasierendem Cholangiokarzinom

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) gab heute bekannt, dass die US-amerikanische Food and Drug Administration (FDA) die Zulassung für Pemazyre™ (Pemigatinib) erteilt hat. Dabei handelt es...
Latest News

Riassunto:  La FDA approva Pemazyre™ (pemigatinib) di Incyte come prima terapia mirata per adulti affetti da colangiocarcinoma metastatico o avanzato che non può essere sottoposto localmente a resezione, già trattato

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte (Nasdaq:INCY) oggi ha annunciato che la FDA (Food and Drug Administration, l’agenzia federale statunitense per gli alimenti e i farmaci) ha approvato...
Latest News

Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Virtual Symposium

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)—- $INCY–Incyte Announces First Presentation of Phase 3 Data from the TRuE-AD Program of Ruxolitinib Cream at the Revolutionizing Atopic Dermatitis Symposia Source...
Latest News

Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–<a href="https://twitter.com/search?q=%24INCY&src=ctag" target="_blank">$INCY</a> <a href="https://twitter.com/hashtag/wcd2019?src=hash" target="_blank">#wcd2019</a>–Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo Source link...
Latest News

Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–lt;a href="https://twitter.com/search?q=%24INCY&amp;src=ctag" target="_blank"gt;$INCYlt;/agt;–Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Chronic Graft-Versus-Host Disease Source link...
Latest News

Incyte veröffentlicht positive Interimsdaten aus einer Phase-2-Studie zu Pemigatinib, seinem selektiven FGFR-Hemmer bei Patienten mit Cholangiokarzinom

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) gab aktualisierte Daten aus seiner FIGHT-202-Studie der Phase 2 zu Evaluierung von Pemigatinib (INCB54828), einem selektiven Hemmer des Fibroblasten-Wachstumsfaktors (FGFR),...
Latest News

Incyte annonce des résultats intermédiaires positifs de l'essai de phase II du Pemigatinib, son inhibiteur sélectif de FGFR, chez les patients atteints de cholangiocarcinome

Newsemia
WILMINGTON, Delaware–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) annonce des résultats actualisés de son étude de phase 2 en cours, FIGHT-202, évaluant le pemigatinib (INCB54828), son inhibiteur sélectif...
Latest News

Incyte annuncia dati intermedi positivi dello studio di fase 2 su pemigatinib, il suo inibitore selettivo dell'FGFR, nei pazienti con colangiocarcinoma

Newsemia
WILMINGTON, Del.–(BUSINESS WIRE)–Incyte Corporation (Nasdaq:INCY) annuncia dati aggiornati dello studio di fase 2 FIGHT-202, in corso di svolgimento, per la valutazione di pemigatinib (INCB54828), il...

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy

COVID-19

COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World